Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Advances in Ophthalmology and OptometryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide.Front Neurol. 2020; 11: 501
- Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis.Curr Opin Neurol. 2020; 33: 47-54
- The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial.Arch Ophthalmol. 1991; 109: 1673-1678
- Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome.Am J Ophthalmol. 2018; 195: 8-15
- Effect of treating acute optic neuritis with bioequivalent oral vs intravenous corticosteroids: a randomized clinical trial.JAMA Neurol. 2018; 75: 690-696
- AQP4-IgG and MOG-IgG related optic neuritis-prevalence, optical coherence tomography findings, and visual outcomes: a systematic review and meta-analysis.Front Neurol. 2020; 11: 540156
- Five-year visual outcomes after optic neuritis in anti-MOG antibody-associated disease.Mult Scler Relat Disord. 2021; 56: 103222
- NMO-IgG predicts the outcome of recurrent optic neuritis.Neurology. 2008; 70: 2197-2200
- Visual field profile of optic neuritis: a final follow-up report from the optic neuritis treatment trial from baseline through 15 years.Arch Ophthalmol. 2010; 128: 330-337
- International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.Neurology. 2015; 85: 177-189
- Contrast-enhanced MRI in acute optic neuritis: relationship to visual performance.Brain. 2002; 125: 812-822
- MRI characteristics of MOG-Ab associated disease in adults: an update.Rev Neurol (Paris). 2021; 177: 39-50
- Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis.Mult Scler. 2016; 22: 470-482
- Prevalence of myelin oligodendrocyte glycoprotein and aquaporin-4-IgG in patients in the optic neuritis treatment trial.JAMA Ophthalmol. 2018; 136: 419-422
- Positive predictive value of myelin oligodendrocyte glycoprotein autoantibody testing.JAMA Neurol. 2021; 78: 741-746
- MOG encephalomyelitis: international recommendations on diagnosis and antibody testing.J Neuroinflammation. 2018; 15: 134
- Corticosteroids for treating optic neuritis.Cochrane Database Syst Rev. 2015; 8: CD001430
- Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?.Neurol Neuroimmunol Neuroinflamm. 2019; 6: e572
- Rapid administration of high-dose intravenous methylprednisolone improves visual outcomes after optic neuritis in patients with AQP4-IgG-positive NMOSD.Front Neurol. 2020; 11: 932
- Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders.J Neurol Neurosurg Psychiatry. 2018; 89: 346-351
- Plasma exchange response in 34 patients with severe optic neuritis.J Neurol. 2016; 263: 883-887
- Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients.Mult Scler. 2014; 20: 501-504
- Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up.Arch Neurol. 2008; 65: 727-732
- Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology.Neurology. 2018; 90: 777-788
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.Lancet Neurol. 2018; 17: 162-173
- Hope for patients with neuromyelitis optica spectrum disorders: from mechanisms to trials.Nat Rev Neurol. 2021; 17: 759-773
- Neuromyelitis spectrum disorders.Mayo Clin Proc. 2017; 9: 663-679
- Evaluation of efficacy and tolerability of first-line therapies in NMOSD.Neurology. 2020; 94: e1645-e1656
- A meta-analysis comparing first-line immunosuppressants in neuromyelitis optica.Ann Clin Transl Neurol. 2021; 8: 2025-2037
- Myelin-oligodendrocyte glycoprotein antibody-associated disease.Lancet Neurol. 2021; 20: 762-772
- Interleukin-6 receptor blockade in treatment-refractory MOG-IgG-associated disease and neuromyelitis optica spectrum disorders.Neurol Neuroimmunol Neuroinflamm. 2022; 9: e1100
- Quantifying axonal loss after optic neuritis with optical coherence tomography.Ann Neurol. 2006; 59: 963-969
- Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica.J Neuroimmunol. 2016; 293: 28-33
- Repeated follow-up of AQP4-IgG titer by cell-based assay in neuromyelitis optica spectrum disorders (NMOSD).J Neurol Sci. 2020; 410: 116671
Article info
Publication history
Published online: June 27, 2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
